UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

@article{Ramachandran2012UKCG,
  title={UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.},
  author={Prakash Ramachandran and Aileen Fraser and Kosh Agarwal and Andrew Austin and Ashley Brown and Graham R. Foster and Rena K. Fox and P C Hayes and Clifford S Leen and Peter R. Mills and David John Mutimer and Stephen D. Ryder and John F. Dillon},
  journal={Alimentary pharmacology & therapeutics},
  year={2012},
  volume={35 6},
  pages={647-62}
}
BACKGROUND The nonstructural 3 serine protease inhibitors (PIs), boceprevir and telaprevir, represent the first in a new generation of directly acting antivirals against genotype 1 hepatitis C (HCV) infection. When used in combination with pegylated interferon and ribavirin, these drugs greatly improve sustained virological response rates in both treatment-naïve patients and patients who have had previous virological failure on treatment. However, the addition of these new agents will increase… CONTINUE READING